SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma

    Usmani SZ (1), Nahi H (2), Mateos MV (3), van de Donk NWCJ (4), Chari A (5), Kaufman JL (6), Moreau P (7), Oriol A (8), Plesner T (9), Benboubker L (10), Hellemans P (11), Masterson T (12), Clemens PL (13), Luo M (12), Liu K (14), San Miguel J (15)

    (1) Levine Cancer Institute/Atrium Health, United States
    (2) Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Sweden.
    (3) Department of Hematology, University Hospital of Salamanca7IBSAL, Spain.
    (4) Hematology, VU University Medical Center, Netherlands.
    (5) Mount Sinai Hospital, United States.
    (6) Hematology and Medical Oncology, Emory University Winship Cancer Institute, United States.
    (7) Department of Hematology, Centre Hospitalier Universitaire de Nantes, France.
    (8) Clinical Hematology, ICO - Hosp Germans Trias i Pujol, Spain.
    (9) Hematology, Vejle Hospital, Denmark.
    (10) Hematology & cell therapy, CHRU TOURS, France.
    (11) Janssen Research & Development, LLC, Belgium.
    (12) Janssen Research & Development, LLC, United States.
    (13) Janssen R&D, United States.
    (14) Biostatistics, Johnson & Johnson PRD, LLC, United States.
    (15) Clinica Universidad de Navarra, Universidad de Navarra, Spain.

    Blood 03 JULY 2019

  • Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Segovia C (1,2,3), San José-Enériz E (2,4), Munera-Maravilla E (1,3), Martínez-Fernández M (1,2,3,5), Garate L (2,6), Miranda E (2,4), Vilas-Zornoza A (2,4), Lodewijk I (1), Rubio C (2,3), Segrelles C (1,2), Valcárcel LV (2,4,7), Rabal O (8), Casares N (9), Bernardini A (1,2), Suarez-Cabrera C (3), López-Calderón FF 1,2,3, Fortes P (10), Casado JA (11), Dueñas M (1,2,3), Villacampa F (2,3), Lasarte JJ (9), Guerrero-Ramos F (3,12), de Velasco G (3,13), Oyarzabal J (8), Castellano D (1,2,13), Agirre X (14,15), Prósper F (16,17,18), Paramio JM (19,20,21).

    (1) Molecular Oncology Unit CIEMAT, Madrid, Spain.
    (2) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (3) Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain.
    (4) Hemato-oncology Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (5) Mobile Genomes and Disease Laboratory CIMUS, Universidad de Santiago de Compostela, La Coruña, Spain.
    (6) Hematology and Cell Therapy Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
    (7) TECNUN, University of Navarra, San Sebastián, Spain.
    (8) Small Molecule Discovery Platform, Molecular Therapeutics Program, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain.
    (9) Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (10) Gene Therapy and Regulation of Gene Expression Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (11) Division of Hematopoietic Innovative Therapies (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras and Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
    (12) Urology Department, University Hospital '12 de Octubre', Madrid, Spain.
    (13) Medical Oncology Department, University Hospital '12 de Octubre', Madrid, Spain.
    (14) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (15) Hemato-oncology Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (16) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (17) Hemato-oncology Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (18) Hematology and Cell Therapy Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
    (19) Molecular Oncology Unit CIEMAT, Madrid, Spain.
    (20) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (21) Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain.

    Nature Medicine 03 JULY 2019

  • Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

    Garcia Garcia Y (1), de Juan Ferré A (2), Mendiola C (3), Barretina-Ginesta MP (4), Gaba Garcia L (5), Santaballa Bertrán A (6), Bover Barcelo I (7), Gil-Martin M (8), Manzano A (9), Rubio Pérez MJ (10), Romeo Marin M (11), Arqueros Núñez C (12), García-Martínez E (13), Gonzalez Martin A (14).

    (1) Medical Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació iInnovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Spain
    (2) Medical Oncology Department, University Hospital Marqués de Valdecilla, Santander, Spain.
    (3) Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
    (4 )Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, Girona, Spain.
    (5) Department of Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, and Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
    (6) Medical Oncology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
    (7) Medical Oncology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain.
    (8) Medical Oncology Department, Catalan Institute of Oncology-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, Barcelona, Spain.
    (9) Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain.
    (10) Medical Oncology, University Hospital Reina Sofia, Córdoba, Spain.
    (11) Medical Oncology Department, Catalan Institute of Oncology, Badalona - Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain.
    (12) Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    (13) Hematology and Medical Oncology Service, University Hospital Morales Meseguer, Murcia, Spain.
    (14) Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.

    International Journal of Gynecological Cancer 01 JULY 2019

  • Venoarterial extracorporeal membrane oxygenation with or without simultaneous intra-aortic balloon pump support as a direct bridge to heart transplantation

    Barge-Caballero G (1,2), Castel-Lavilla MA (3), Almenar-Bonet L (4), Garrido-Bravo IP (2,5), Delgado JF (2,6), Rangel-Sousa D (7), González-Costello J (8), Segovia-Cubero J (2,9), Farrero-Torres M (3), Lambert-Rodríguez JL (10,11), Crespo-Leiro MG (1,2), Hervás-Sotomayor D (12), Portolés-Ocampo A (13), Martínez-Sellés M (2,14), De la Fuente-Galán L (2,15), Rábago-Juan-Aracil G (16), González-Vílchez F (17), Mirabet-Pérez S (18), Muñiz J (2,19), Barge-Caballero E (1,2).

    (1) Complejo Hospitalario Universitario A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain.
    (2) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
    (3) Hospital Clinic i Provincial, Barcelona, Spain.
    (4) Hospital Universitario y Politécnico La Fe, Valencia, Spain.
    (5) Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
    (6) Hospital Universitario Doce de Octubre, Instituto de Investigación i+12, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
    (7) Hospital Universitario Virgen del Rocío, Sevilla, Spain.
    (8) Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain.
    (9) Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
    (10) Hospital Universitario Central de Asturias, Oviedo, Spain.
    (11) Universidad Católica San Antonio, Murcia, Spain.
    (12) Hospital Universitario Reina Sofía, Córdoba, Spain.
    (13) Hospital Universitario Miguel Servet, Zaragoza, Spain.
    (14) Hospital General Universitario Gregorio Marañón, Universidad Complutense, Universidad Europea, Madrid, Spain.
    (15) Hospital Clínico Universitario, Valladolid, Spain.
    (16) Clínica Universidad de Navarra, Pamplona, Spain.
    (17) Hospital Universitario Marqués de Valdecilla, Santander, Spain.
    (18) Hospital Santa Creu i Sant Pau, Barcelona, Spain.
    (19) Instituto Universitario de Ciencias de la Salud, Universidad de A Coruña (UDC), INIBIC, A Coruña, Spain.

    Interactive Cardiovascular and Thoracic Surgery 30 JUNE 2019

  • Preclinical safety of topically administered nanostructure lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies

    Vairo C (1), Collantes M (2), Quincoces G (2), Villullas S (3), Peñuelas I  (4), Pastor M (3), Gil AG (5), Gainza E (3), Hernandez RM (6), Igartua M (6), Gainza G (7).

    (1) BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510 Miñano, Araba, Spain; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
    (2) Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510 Miñano, Araba, Spain.
    (4) Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain; Small Animal Imaging Research Unit, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain; Toxicology Unit, Drug Development Unit University of Navarra (DDUNAV), 31008 Pamplona, Spain.
    (6) NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
    (7) BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510 Miñano, Araba, Spain

    International Journal of Pharmaceutics 28 JUNE 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra